Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
high-dose interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
High-dose interferon (HDI) refers to the use of large doses of the cytokine drug interferon alfa-2b, most commonly in the adjuvant treatment of melanoma. Interferons are naturally occurring proteins with antiviral, antiproliferative, and immunomodulatory effects. In oncology, HDI is used to stimulate immune responses against tumor cells. The mechanism involves binding to cell surface receptors and activating intracellular signaling pathways that enhance immune surveillance and inhibit tumor proliferation. High-dose regimens are associated with significant toxicity but have been shown to improve relapse-free survival in certain populations with high-risk melanoma.
- Other names
- high-dose interferonHDI therapyhigh-dose interferon alfa-2b therapy
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on high-dose interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on high-dose interferon alfa-2b.